By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Aerpio Therapeutics 

9987 Carver Road
Suite 420
Cincinnati  Ohio  45242  U.S.A.
Phone: 513-985-1920 Fax: 513-985-0999


Aerpio Therapeutics is a new, clinical-stage biotechnology company focused on the development of novel small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Aerpio was created in a spin-out transaction from Akebia Therapeutics to enable more rapid development of its exciting compounds.

Aerpio's two lead programs include a Tie-2 activator for diabetic macular edema (DME) and vascular leak, and a Hypoxia-inducible Factor 1-a (HIF1-a) stabilizer for wound healing and the treatment of inflammatory bowel disease. The lead compound for the Tie-2 program, AKB-9778, is currently completing its initial Phase 1 clinical trial, and the HIF1-a stabilization program is progressing toward the clinic with support, in part, from the United States Department of Defense and National Institutes of Health.

The Aerpio team is composed of highly experienced individuals from all facets of pharmaceutical development. During the last 4 years, this team has successfully sharpened their skills at Akebia Therapeutics in the fast paced world of venture backed biopharmaceuticals.

Key Statistics

Ownership: Private

Web Site: Aerpio
Employees: n/a


Company News
Aerpio Completes Enrollment Of Phase 2 Study Of Tie2 Activator AKB-9778 For The Treatment Of Patients With Diabetic Macular Edema 12/4/2014 9:41:42 AM
Top 30 Life Science Startups To Watch In The U.S. 10/23/2014 4:27:21 AM
Aerpio Announces Publication Of Preclinical Data On AKB-9778 For Common Eye Diseases 9/3/2014 12:48:40 PM
Aerpio Presents Full Results From Phase 1b/2a Study Of AKB-9778 For The Treatment Of Diabetic Macular Edema At Association for Research in Vision & Ophthalmology Annual Meeting 5/5/2014 9:54:32 AM
Aerpio Closes $22 Million Financing 4/23/2014 8:31:02 AM
Aerpio Initiates Phase 2 Study Of Tie2 Activator AKB-9778 For The Treatment Of Diabetic Macular Edema 2/13/2014 9:12:37 AM
Aerpio Announces Successful Completion of Phase 1b/2a Trial in Diabetic Macular Edema and $9 Million Series A Extension 11/6/2013 10:13:55 AM
Aerpio Announces Publication of Data on Tie2 Activator, AKB-9778, Supporting Future Clinical Development in Cancer 8/5/2013 9:39:45 AM
Aerpio Initiates Phase 1b/2a Trial of AKB-9778 in Diabetic Macular Edema 9/19/2012 10:06:25 AM
Aerpio Raises $27 Million 8/31/2012 7:49:03 AM